CD200, a cell surface ligand that plays a role in regulating the immune system, has been shown to be upregulated on the surface of some hematologic and solid tumor malignancies. The purpose of the current study was to study CD200 expression in patients with different B Chronic lymphoproliferative disorders (BLPDs) and to evaluate whether adding CD200 to the flow cytometry routine panels of BCLPDs could improve the ability of differential diagnosis of these disorders. Tricolor Flowcytometry immunophenotyping (FCIP) was used to evaluate CD200 expression on malignant clone cells in 49 patients with leukemic phase of chronic B lymphoproliferative disorders, as well as 13 age and sex matched normal control volunteers. CD200 was evaluated on CD5/19 positive clone in 31 patients with B-Chronic lymphocytic leukemia (B-CLL), while it was evaluated on CD19/22 positive clone in 12 patients with non-Hodgkin lymphoma (NHL), 4 patients with mantle cell lymphoma (MCL) and 2 patients with hairy cell leukemia (HCL). Results showed that CD200 was brightly expressed on 60 to 100% of CD5/19 positive clone in all B-CLL patients while in all the patients of other BCLPDs, including MCL, the expression was below the cutoff of positivity value (20%) and with a dim pattern, with the exception of HCL, in which CD200 was strongly and brightly expressed. These results can point to the importance of adding CD200 to the BCLPDs flowcytometric routine panels and we propose to add CD200 beside the Matutes scoring system after being validated by further studies. These data have also to be considered in view of the proposed anti-CD200 targeted therapy in CD200-expressing tumors in particular for B CLL and HCL representing new promising therapeutic strategies.